Related references
Note: Only part of the references are listed.HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Beatriz Mothe et al.
FRONTIERS IN IMMUNOLOGY (2020)
Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens
Chengcheng Zou et al.
JOURNAL OF VIROLOGY (2019)
Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
Nathifa Moyo et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
Tomas Hanke
EXPERT REVIEW OF VACCINES (2019)
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
Beatriz Mothe et al.
ECLINICALMEDICINE (2019)
A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
Staci Sabnis et al.
MOLECULAR THERAPY (2018)
CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication
Hayato Murakoshi et al.
RETROVIROLOGY (2018)
An RNA toolbox for cancer immunotherapy
Fernando Pastor et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells
Edmund G. Wee et al.
MOLECULAR THERAPY (2017)
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek et al.
GENOME MEDICINE (2017)
Modified mRNA Vaccines Protect against Zika Virus Infection (vol 168, pg 1114, 2017)
Justin M. Richner et al.
CELL (2017)
HIV-Host Interactions: Implications for Vaccine Design
Barton F. Haynes et al.
CELL HOST & MICROBE (2016)
Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection
Beatrice Ondondo et al.
MOLECULAR THERAPY (2016)
Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine
James Theiler et al.
SCIENTIFIC REPORTS (2016)
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults
Gaudensia Mutua et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes
Hayato Murakoshi et al.
JOURNAL OF VIROLOGY (2015)
Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1
Nicola Borthwick et al.
MOLECULAR THERAPY (2014)
The T-Cell Response to HIV
Bruce Walker et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Definition of the viral targets of protective HIV-1-specific T cell responses
Beatriz Mothe et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
Nilu Goonetilleke et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
Sven Letourneau et al.
PLOS ONE (2007)
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
Will Fischer et al.
NATURE MEDICINE (2007)
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes
N Frahm et al.
NATURE IMMUNOLOGY (2006)
Share Paper
